Valuation: Jazz Pharmaceuticals plc

Market Cap 14.02B 12.56B 11.55B 10.47B 19.56B 1,331B 19.93B 138B 55.29B 700B 52.62B 51.5B 2,208B P/E 2026 *
35.9x
P/E 2027 * 13.3x
Enterprise Value 16.47B 14.75B 13.57B 12.3B 22.99B 1,564B 23.42B 162B 64.97B 823B 61.83B 60.51B 2,595B EV / Sales 2026 *
3.48x
EV / Sales 2027 * 2.91x
Free-Float
96.83%
Yield 2026 *
-
Yield 2027 * -
1 day+3.92%
1 week+0.93%
Current month-6.71%
1 month-6.71%
3 months-16.41%
6 months+6.38%
Current year+27.05%
1 week 202.3
Extreme 202.3
216.62
1 month 202.3
Extreme 202.3
238.87
Current year 156.95
Extreme 156.95
266.38
1 year 128.8
Extreme 128.8
266.38
3 years 95.49
Extreme 95.49
266.38
5 years 95.49
Extreme 95.49
266.38
10 years 86.88
Extreme 86.88
266.38
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-10
Director of Finance/CFO 62 2024-02-29
Chief Tech/Sci/R&D Officer 54 2023-07-31
Director TitleAgeSince
Chairman 62 2003-02-28
Director/Board Member 65 2012-01-17
Director/Board Member 66 2009-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Sell

Chief Executive Officer

-2,000 0.0031%
10/1/26 Sell

Founder

-6,000 0.0092%
9/10/26 Sell

General Counsel

-1,200 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
+3.92%+0.93%+58.46%+72.84% 14.02B
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +1.95%+5.40%+47.78%+82.11% 427.59B
Weighted average by Cap. +1.20%+6.58%+50.90%+98.23%

Financials

2026 *2027 *
Net sales 4.74B 4.24B 3.9B 3.54B 6.61B 450B 6.73B 46.54B 18.68B 237B 17.78B 17.4B 746B 5.02B 4.49B 4.13B 3.74B 7B 476B 7.13B 49.28B 19.78B 251B 18.83B 18.43B 790B
Net income 410M 367M 338M 306M 572M 38.93B 583M 4.03B 1.62B 20.48B 1.54B 1.51B 64.58B 1.13B 1.01B 929M 841M 1.57B 107B 1.6B 11.07B 4.45B 56.3B 4.23B 4.14B 178B
Net Debt 2.45B 2.2B 2.02B 1.83B 3.42B 233B 3.49B 24.11B 9.68B 123B 9.21B 9.01B 387B 584M 523M 481M 436M 814M 55.41B 829M 5.73B 2.3B 29.15B 2.19B 2.14B 91.92B
Projected Income Statement - Annual - Jazz Pharmaceuticals plc
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
26-10-30 $215.98 +3.92% 1,215,115
26-10-29 $207.83 +1.35% 773,588
26-10-28 $205.06 -0.83% 816,165
26-10-27 $206.78 +0.53% 605,813
26-10-26 $205.70 -3.88% 970,043
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Jazz Pharmaceuticals plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
215.98USD
Average target price
295.36USD
Spread / Average Target
+36.76%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Jazz Pharmaceuticals plc
  1. Stock Market
  2. Stocks
  3. JAZZ Stock